Translating Toxicity Profiles of Amanitin-Based ADCs From Nonclinical Models to Clinical Studies & Leveraging the Knowledge to Guide Dose Optimization
Time: 3:45 pm
day: Scientific Program Day One
Details:
- Examining how the nonclinical profile of HDP-101 can predict clinical safety and efficacy outcomes
- Comparing the PK and toxicity profile of amanitin-based ADCs between nonclinical models, predictive modelling and patients
- Exploring strategies to refine the pharmacokinetics and optimize the dosing regimens of HDP-101 to improve the therapeutic window
